Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review

Table 3 Comparison of the hepatic safety outcomes in the efruxifermin vs placebo arms

Outcome variables	EFX dose (mg)	No. of study reports	No. of participants with outcome analyzed		Pooled effect size, MD (95%CI)	P value (EFX vs placebo)	I2 (%)	P value (EFX 28 vs 50)
			EFX arm	Placebo arm
ALT (U/L)	28	3	118	125	-16.52 (-29.54 to -3.51)	0.01	87	0.96
	50	5	165	145	-16.93 (-28.38 to -5.48)	0.004	92
AST (U/L)	28	3	118	125	-14.62 (-21.72 to -7.53)	< 0.0001	74	0.81
	50	5	165	145	-13.35 (-20.94 to -5.75)	0.0006	89
ALP (U/L)	28	3	118	125	-2.13 (-10.52 to 6.26)	0.62	86	0.64
	50	5	165	145	-4.46 (-9.61 to 0.70)	0.09	64
GGT (U/L)	28	3	118	125	-16.52 (-29.54 to -3.51)	0.01	87	0.96
	50	5	165	145	-16.93 (-28.38 to -5.48)	0.004	92
Urate (mg/dL)	28	3	112	124	-0.73 (-1.06 to -0.41)	< 0.0001	64	0.63
	50	5	158	134	-0.59 (-1.06 to -0.12)	0.01	85

ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; EFX: Efruxifermin; GGT: Gamma-glutamyl transferase; MD: Mean difference.